Christopher Marai
Stock Analyst at Nomura
(2.42)
# 2,570
Out of 5,090 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $10.24 | +9,275.00% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $89.65 | -63.19% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $5.77 | +1,459.79% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $458.12 | -83.85% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $4.28 | +273.83% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $181.30 | +116.22% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.99 | +1,608.54% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $22.26 | +933.24% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $20.32 | -40.94% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $11.07 | +71.64% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $4.74 | +807.17% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $10.24
Upside: +9,275.00%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $89.65
Upside: -63.19%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $5.77
Upside: +1,459.79%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $458.12
Upside: -83.85%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $4.28
Upside: +273.83%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $181.30
Upside: +116.22%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.99
Upside: +1,608.54%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $22.26
Upside: +933.24%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $20.32
Upside: -40.94%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $11.07
Upside: +71.64%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $4.74
Upside: +807.17%